Skip to content
Homepage
Author:
Zenas BioPharma
Posted Date:
June 17, 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma
June 17, 2026
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Zenas BioPharma
June 11, 2026
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
Zenas BioPharma
June 2, 2026
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
Zenas BioPharma
May 29, 2026
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
Zenas BioPharma
May 28, 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma
May 28, 2026
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Zenas BioPharma
May 27, 2026
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma
May 27, 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma
May 24, 2026
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
Zenas BioPharma
May 21, 2026
1
2
Next
